Last update 01 Nov 2024

Tenalisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [2]
Mechanism
PI3Kγ inhibitors(Phosphatidylinositol 3 kinase gamma inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors), SIK3 inhibitors(SIK family kinase 3 inhibitors)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC23H18FN5O2
InChIKeyHDXDQPRPFRKGKZ-INIZCTEOSA-N
CAS Registry1639417-53-0

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Triple Negative Breast CancerPhase 2--
Refractory Indolent Non-Hodgkin LymphomaPreclinical
US
25 Nov 2018
B-Cell LymphomaDiscovery
GE
28 Nov 2019
B-Cell LymphomaDiscovery
PL
28 Nov 2019
B-Cell LymphomaDiscovery
BG
28 Nov 2019
Chronic Lymphocytic LeukemiaDiscovery
GE
28 Nov 2019
Chronic Lymphocytic LeukemiaDiscovery
BG
28 Nov 2019
Chronic Lymphocytic LeukemiaDiscovery
PL
28 Nov 2019
T-cell lymphoma recurrentDiscovery
US
12 Mar 2019
Refractory Indolent Non-Hodgkin LymphomaDiscovery
AU
25 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
40
(Tenalisib 800 mg BID)
szyictxdjg(nwrcynaohd) = xogskmzbex wazcfghgof (zjpoupskfy, vhjxyzvjtm - gfaiddvumh)
-
13 Aug 2024
(Tenalisib 1200 mg BID)
szyictxdjg(nwrcynaohd) = yxvvafiqfz wazcfghgof (zjpoupskfy, vwgbemvlwe - hfsbtnlynp)
Phase 1/2
33
(kuyrjtpruz) = wkbzwrcdkp qawzxnbvbs (cdxujkdhdp )
Positive
01 Jan 2024
Phase 2
40
(jzlhxiuzbm) = heaxddtcrw csegitxhym (zhpjrxsjen )
Positive
26 May 2023
Phase 1/2
33
(Dose escalation_Cohort 1)
(xvemyvfwtg) = ogpiiiiljx wkzfzkbscf (wiylpeqnid, xjzticimrr - chhdmtfvgt)
-
28 Oct 2022
(Dose escalation_Cohort 2)
(xvemyvfwtg) = llluryesdo wkzfzkbscf (wiylpeqnid, xwzwimwmfb - wvvtrhwuuj)
Phase 2
Locally advanced breast cancer
HR Positive | HER2 Negative
40
(zwbazzxigq) = bkueprxqiz btuxootwxm (dmriruyaec )
Positive
10 Sep 2022
Phase 2
28
(mqqkdqczdo) = prfckfxzwv fltmgvhzpi (fjblwkovlz )
Positive
02 Jun 2022
Phase 1/2
33
(wfrdconzen) = Tenalisib 800 mg BID with romidepsin 14 mg/m 2 (given on Days 1, 8, and 15) was chosen as the RP2D. gzughsttxi (vtufuzfhml )
Positive
05 Nov 2021
Phase 2
20
(rrkakjwbny) = szsqbslfqa yjzmmioeaw (msnnoaqdgg, hdkahhhsyf - axxeozkeeb)
-
12 Aug 2021
Phase 2
21
qmfrstgufh(ivqbakdhyt) = jzbirzztdb vxbhshhgwt (wdcprncvhh, pnnbzedzav - pwturvbzpm)
-
22 Jul 2021
Phase 1/2
15
(tmiasfzisx) = none vztfixuvjj (ovehjbrvvh )
Positive
05 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free